<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670761</url>
  </required_header>
  <id_info>
    <org_study_id>2.2.1</org_study_id>
    <nct_id>NCT00670761</nct_id>
  </id_info>
  <brief_title>Misoprostol for the Treatment of Incomplete Abortion</brief_title>
  <official_title>Misoprostol for the Treatment of Incomplete Abortion: Comparison of Treatment Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Befelatanana Maternity Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Municipal Clinical Hospital No. 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kagera Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jose Macamo Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tudu hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National OBGYN hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cuchi General District hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de District Sanitaire Dandé</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de District Sanitaire de Ziniaré</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study will examine the efficacy, safety and acceptability of misoprostol for
      treatment of incomplete abortion.

      Women diagnosed with incomplete abortion will be randomized to receive one of the following
      regimens:

      In Tanzania and Mozambique:

        1. 600 mcg of oral misoprostol in one dose, or

        2. Standard surgical treatment (MVA)

      In Moldova and Madagascar:

        1. 600 mcg of oral misoprostol in one dose, or

        2. 400 mcg of sublingual misoprostol in one dose.

      In Burkina Faso and Vietnam:

      1. 400 mcg of sublingual misoprostol in one dose.

      We hypothesize that treatment of incomplete abortion with either 400 mcg sublingual
      misoprostol, 600 mcg oral misoprostol or MVA are equally effective in evacuating the uterus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not available
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete resolution of signs/symptoms of incomplete abortion without recourse to surgery at any point for any reason</measure>
    <time_frame>one week after initial treatment with the option of an additional week</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Abortion, Incomplete</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 600mcg oral misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 400mcg sublingual misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with Manual Vacuum Aspiration (MVA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MVA</intervention_name>
    <description>comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If no ultrasound used:

               1. Past or present history of vaginal bleeding during pregnancy; and

               2. Open cervical os.

          -  If ultrasound used:

               1. Past or present history of vaginal bleeding during pregnancy; and

               2. Evidence of incomplete abortion with substantial debris in the uterus.

        All women would have been advised to have surgical evacuation of the uterus if misoprostol
        was not available.

          -  Willing to provide contact information for purposes of follow-up.

               -  In Tanzania: 18 years of age or over or parental permission

               -  In Mozambique: 21 years of age or over or parental permission

               -  In Moldova: 18 years of age or over

               -  In Madagascar: 18 years of age or parental permission

               -  In Vietnam: reproductive age

        Exclusion Criteria:

          -  Contraindications to the study drug;

          -  Uterine size larger than 12 weeks L.M.P. at time of presentation for care.

          -  Signs of severe infection, defined as at least one of the following of:

               1. foul smelling discharge,

               2. fever &gt; 39 degrees C ,

               3. pulse &gt;110/min;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de District Sanitaire Dandé</name>
      <address>
        <city>Bobo Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de District Sanitaire de Ziniaré</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Befelatanana Maternity Centre</name>
      <address>
        <city>Antananarivo</city>
        <country>Madagascar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital</name>
      <address>
        <city>Chishinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jose Macamo Hospital</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagera Regional Hospital</name>
      <address>
        <city>Bukoba</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Madagascar</country>
    <country>Moldova, Republic of</country>
    <country>Mozambique</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2008</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>incomplete abortion</keyword>
  <keyword>sublingual</keyword>
  <keyword>postabortion care</keyword>
  <keyword>MVA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Incomplete</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

